Global PARP (Poly ADP-Ribose Polymerase) Inhibitor market will reach 8800 million US$ by the end of 2025

Publisher: QYResearch

Published Date: 2019/11/22

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at 1205 million US$ in 2018 is expected to reach 8800 million US$ by the end of 2025, growing at a CAGR of 32.8% during 2019-2025.

Click to view the full report: https://www.qyresearch.com/index/detail/828980/global-parp-poly-adp-ribose-polymerase-inhibitor-industry

This article was first released by QYResearch, if reproduced, please indicate the source.

Marketing: sales@qyresearchglobal.com

Media Contact: press@qyresearch.com